Artificial Intelligence and Clinical Decision Support in Telehealth

Artificial intelligence and clinical decision support (CDS) tools are reshaping how diagnostic reasoning, triage, and treatment guidance function within telehealth delivery systems. This page covers the technical definitions, regulatory frameworks, operational mechanics, and classification distinctions that govern AI-assisted CDS in remote care settings. The intersection of algorithmic tools with federal oversight from agencies including the FDA, ONC, and CMS creates a layered compliance environment distinct from in-person clinical AI applications. Understanding these boundaries is essential for clinicians, platform developers, health systems, and policymakers operating in this space.

• Definition and Scope
• Core Mechanics or Structure
• Causal Relationships or Drivers
• Classification Boundaries
• Tradeoffs and Tensions
• Common Misconceptions
• Checklist or Steps
• Reference Table or Matrix

Definition and Scope

Clinical decision support encompasses software that analyzes patient data and presents clinicians — or patients — with actionable knowledge at the point of care. The Office of the National Coordinator for Health Information Technology (ONC) defines CDS broadly as tools that provide clinicians, staff, patients, or other individuals with knowledge and person-specific information, intelligently filtered or presented at appropriate times, to enhance health and healthcare decisions.

Within telehealth, AI-powered CDS takes on additional complexity because the clinical encounter occurs across a network connection, often with limited physical examination data, and increasingly with inputs from remote patient monitoring devices and wearable sensors. The scope of AI-CDS in telehealth includes:

• Symptom checkers and triage algorithms that direct patient routing before or during synchronous visits
• Diagnostic support tools that process structured and unstructured data to surface differential diagnoses
• Risk stratification engines that flag deteriorating patients in chronic disease management programs
• Natural language processing (NLP) tools that extract clinical meaning from clinician notes or patient-reported text
• Predictive analytics platforms embedded in EHR systems integrated with telehealth platforms

The 21st Century Cures Act (Pub. L. 114-255), enacted in 2016, explicitly addressed CDS software and created a partial exemption from FDA device regulation for certain low-risk decision support functions, establishing a framework that continues to govern much of the field.

Core Mechanics or Structure

AI-based CDS systems in telehealth operate across four functional layers:

1. Data Ingestion Layer
Patient data enters the system from multiple sources: structured EHR data (ICD-10 codes, labs, vitals), unstructured clinical notes, patient-reported outcomes, and sensor data from connected devices. In asynchronous telehealth workflows, this layer may process store-and-forward image files or audio recordings without real-time clinician involvement.

2. Model Layer
Machine learning models — including logistic regression, gradient-boosted trees, convolutional neural networks (CNNs), and large language models (LLMs) — process ingested data. CNN architectures are particularly common in image-based applications such as teledermatology and teleradiology. Recurrent models and transformer architectures handle time-series patient monitoring data and free-text interpretation.

3. Output Generation Layer
Models produce outputs in one of three forms: alerts and reminders (e.g., drug interaction warnings), order sets and care pathways, or risk scores with associated explanations. The explainability of these outputs — whether a clinician can understand why a recommendation was generated — is a specific area of regulatory focus.

4. Human-in-the-Loop Integration
ONC and FDA guidance consistently distinguishes between tools that present information for clinician review versus tools that autonomously act on patient data. The human-in-the-loop requirement shapes how CDS outputs must be surfaced and documented within telehealth platforms.

The Health Level Seven International (HL7) FHIR (Fast Healthcare Interoperability Resources) standard underpins data exchange between AI-CDS tools and EHR or telehealth platforms. CDS Hooks, a HL7-developed specification, defines a standard mechanism for invoking CDS services at specific clinical workflow moments (e.g., when a prescription is initiated or a visit note is opened).

Causal Relationships or Drivers

Three primary forces have driven AI-CDS adoption within telehealth:

Encounter Volume and Time Constraints
Telehealth visits — particularly in direct-to-consumer platforms and urgent care settings — compress diagnostic workflows. Clinicians conducting 15–20-minute remote encounters have less time for record review; AI-CDS tools that surface relevant history or flag abnormal patterns address this constraint directly.

Data Density from Remote Monitoring
Continuous sensor data from cardiac monitors, glucose sensors, and pulse oximeters generates volumes of patient data that exceed unaided clinician processing capacity. In telehealth cardiology and remote monitoring programs, AI tools serve as the primary filter between raw device output and actionable clinical events.

Regulatory Tailwinds from the 21st Century Cures Act
By exempting certain CDS software from FDA device classification, the 2016 Cures Act reduced the regulatory cost of deploying low-risk decision support in digital health platforms, accelerating product development cycles. The FDA's September 2022 guidance document, Clinical Decision Support Software, operationalized these exemptions and defined a risk-tiered classification approach.

Workforce Distribution Pressures
Specialist shortages in rural health settings and underserved communities create demand for AI tools that extend diagnostic capability into low-resource environments. Algorithms validated for retinal disease screening or dermatologic lesion classification can function where specialist access is absent.

Classification Boundaries

The FDA's 2022 CDS Software guidance establishes a four-condition test for non-device CDS. A software function qualifies for exemption only if it:

1. Is not intended to acquire, process, or analyze medical images or signals from in vitro diagnostics or signal acquisition hardware
2. Displays, analyzes, or prints medical information that is generally accepted in medicine
3. Supports or provides recommendations to a healthcare professional about prevention, diagnosis, or treatment of a disease
4. Enables the healthcare professional to independently review the basis for the recommendation — the "transparent basis" requirement

Software failing any one of these four conditions is regulated as a Software as a Medical Device (SaMD) under FDA oversight, subject to 21 CFR Part 820 quality system requirements and, depending on risk classification, 510(k) clearance or Premarket Approval (PMA).

The International Medical Device Regulators Forum (IMDRF) SaMD classification framework uses a 2×2 risk matrix based on the significance of information provided (treat/diagnose vs. inform) and the healthcare situation or condition (critical vs. serious vs. non-serious). FDA has adopted this IMDRF framework as a reference in its SaMD guidance.

AI-CDS tools that process images autonomously — such as FDA-cleared diabetic retinopathy screening algorithms — sit unambiguously within the SaMD category. As of 2023, the FDA had authorized more than 700 AI/ML-enabled medical devices (FDA AI/ML Action Plan), the majority concentrated in radiology and cardiology applications.

Tradeoffs and Tensions

Accuracy vs. Explainability
High-performing deep learning models — particularly neural networks processing imaging data — often operate as black boxes with limited interpretability. FDA guidance on the transparent basis requirement creates tension with these architectures, since the technical basis for a CNN's classification may not be reducible to a clinician-readable rationale without specialized explainability frameworks (e.g., SHAP values, LIME).

Generalizability vs. Local Validity
A model trained on data from large academic medical centers may perform poorly when deployed in a rural telehealth context with different patient demographics, device types, or documentation practices. The FDA's proposed framework for Predetermined Change Control Plans (PCCPs) addresses continuous learning models, but local validation remains an institutional responsibility not fully resolved by federal guidance.

Speed vs. Oversight
Real-time AI alerts can interrupt clinician workflow with low-specificity flags, producing alert fatigue — a documented phenomenon in hospital settings. In telehealth environments with abbreviated encounter windows, poorly calibrated alert thresholds may degrade rather than support clinical decision quality.

Innovation Velocity vs. Regulatory Cadence
The pace of LLM development and deployment in clinical applications has outpaced the FDA's ability to issue device-specific guidance. Ambient AI documentation tools and LLM-based clinical summarizers occupy a regulatory gray zone that ONC, CMS, and FDA are still actively defining as of the agency's 2024 proposed rulemaking cycles.

Common Misconceptions

Misconception: All AI-CDS tools require FDA clearance.
Correction: The 21st Century Cures Act and FDA's 2022 CDS guidance explicitly exempt low-risk CDS tools meeting the four-condition test. Symptom checkers and clinical calculator tools that present transparent, generally accepted information to clinicians for independent review are not regulated as medical devices.

Misconception: FDA clearance of an AI tool means it is clinically validated for all patient populations.
Correction: FDA authorization confirms a device meets a specific safety and effectiveness standard at the time of clearance. Post-market performance monitoring, demographic subgroup validation, and site-specific calibration remain distinct processes not guaranteed by clearance status.

Misconception: HIPAA compliance fully addresses AI-CDS data governance.
Correction: HIPAA (45 CFR Parts 160 and 164) governs protected health information handling by covered entities and business associates. It does not address algorithmic bias, model audit requirements, or post-market surveillance obligations. ONC's information blocking rules and the HTI-1 final rule (88 FR 23746) establish separate algorithmic transparency requirements for EHR-certified technology.

Misconception: AI tools used by patients directly (consumer apps) are unregulated.
Correction: Mobile medical apps that meet the definition of a medical device under 21 USC 321(h) are subject to FDA oversight. The FDA's Mobile Medical Applications guidance distinguishes regulated apps from wellness or administrative tools based on intended use and risk level.

Checklist or Steps

The following sequence describes the typical framework elements involved in evaluating AI-CDS tools for telehealth deployment, as structured by ONC certification criteria, FDA guidance, and NIST risk management principles. This is a reference taxonomy, not professional or legal guidance.

Phase 1: Regulatory Classification
- [ ] Determine whether the tool meets all four conditions for non-device CDS under FDA's 2022 CDS Software guidance
- [ ] Assess whether the tool acquires or processes medical images, signals, or IVD outputs (triggers SaMD classification)
- [ ] Identify whether the tool is intended for professional use, patient use, or both (affects FDA classification pathway)
- [ ] Confirm whether FDA 510(k) clearance, De Novo authorization, or PMA has been obtained if SaMD classification applies

Phase 2: Data Governance Review
- [ ] Confirm business associate agreement (BAA) coverage under HIPAA for any vendor processing PHI
- [ ] Review ONC HTI-1 algorithmic transparency disclosures if the tool is embedded in a certified EHR
- [ ] Identify data sources used in model training and whether they include federally protected data categories (42 CFR Part 2 for substance use disorder records)

Phase 3: Clinical Validation Assessment
- [ ] Review published research-based validation studies for the specific patient population and care setting
- [ ] Confirm whether demographic subgroup performance data (age, race, sex, comorbidity) has been disclosed
- [ ] Identify model version and assess whether the deployed version matches the validated version

Phase 4: Integration and Workflow Mapping
- [ ] Map CDS output types (alerts, order sets, risk scores) to specific clinical workflow moments
- [ ] Assess whether the tool uses HL7 FHIR CDS Hooks or proprietary integration protocols
- [ ] Document human-in-the-loop override mechanisms and audit trail requirements

Phase 5: Ongoing Monitoring
- [ ] Establish performance benchmarks tied to telehealth quality metrics
- [ ] Identify responsible party for post-market surveillance under FDA's PCCP framework if applicable
- [ ] Schedule periodic bias audits using NIST AI Risk Management Framework (NIST AI RMF 1.0) guidance

Reference Table or Matrix

AI-CDS Regulatory Classification Matrix

Key Federal Statutes and Guidance Documents

References

• [Office of the National Coordinator for Health Information Technology (ONC) — Clinical Decision Support](